425: BioNTech to Acquire CureVac, Bolstering mRNA Pipeline

BioNTech SE announces an all-stock offer to acquire CureVac N.V., aiming to significantly expand its mRNA-based oncology and infectious disease capabilities, despite projecting a net loss for 2025.

Summary

• BioNTech SE is offering to acquire all issued ordinary shares of CureVac N.V. (Nasdaq: CVAC) in an all-stock transaction.
• The offer consideration is newly registered BioNTech American Depositary Shares (ADSs), with an Exchange Ratio determined by dividing $5.4641 by the BioNTech ADS Volume-Weighted Average Price (VWAP), subject to collar adjustments (0.04318 if VWAP >= $126.55, 0.06476 if VWAP <= $84.37).
• Fractional ADSs will be paid in cash.
• The offer commences on October 21, 2025, and is initially set to close on December 3, 2025.
• CureVac shareholders representing approximately 57% of shares (including dievini Hopp BioTech holding GmbH & Co. KG, KfW, Glaxo Group Limited, and CureVac board members) have committed to tendering their shares.
• The acquisition is expected to provide significant strategic benefits, expanding BioNTech's mRNA capabilities in oncology, including target discovery, production, mRNA design, and delivery formulations.
• Total costs related to the offer are estimated at approximately 17.5 million euros.
• The transaction is subject to customary closing conditions, including a minimum tender condition of 80% (reducible to 75%) of CureVac's share capital and necessary antitrust approvals.
• Post-offer reorganization will involve a Dutch legal downstream merger of CureVac into a new BioNTech subsidiary, followed by the sale of CureVac SE's shares to BioNTech and cancellation of New Topco A Shares.
• Non-tendering CureVac shareholders in the post-offer reorganization may be subject to Dutch dividend withholding tax (15%) on the cancellation consideration, which is not applicable to those who tender in the offer.
• Dilution for new BioNTech shareholders (former CureVac shareholders) is estimated between (6.0)% and 38.2%, while existing BioNTech shareholders face dilution of (0.5)% to 1.5%, depending on the final exchange ratio.
• BioNTech expects to incur a net loss for the 2025 financial year.
• Revenues for the six months ended June 30, 2025, increased by 40.2% to 443.6 million euros compared to 316.3 million euros in the same period of 2024.
• Operating loss decreased by 30% to 1,035.2 million euros for the six months ended June 30, 2025, from 1,473.4 million euros in the prior year period.
• Net loss decreased by 29% to 802.4 million euros for the six months ended June 30, 2025, from 1,122.9 million euros in the prior year period.
• Cash and cash equivalents stood at 10,269.5 million euros as of June 30, 2025, with total cash, cash equivalents, and security investments at 15,989.3 million euros.

Sentiment

Score: 5

Explanation: The filing presents a mixed bag of strategic advancements and significant financial challenges. While the acquisition of CureVac and the BMS collaboration represent strong strategic moves to diversify the pipeline and secure substantial funding, the company explicitly forecasts a net loss for 2025 and faces ongoing patent litigation, clinical trial setbacks (futility boundary crossed, clinical hold, program discontinuations), and declining COVID-19 vaccine revenues. The long-term vision is positive, but near-term financial performance and operational risks create a neutral-to-slightly-negative sentiment.

Positives

• Strategic acquisition of CureVac is expected to expand mRNA capabilities in oncology, including target discovery, production, mRNA design, and delivery formulations.
• The acquisition complements BioNTech's existing oncology pillars, including immunomodulators and antibody-drug conjugates (ADCs).
• Strong commitment from major CureVac shareholders, representing approximately 57% of shares, to tender their holdings.
• Anticipated elimination of duplicative public company costs post-acquisition.
• Positive preliminary clinical data for BNT327 (bispecific antibody) in various solid tumors, including PD-L1-low/negative tumors, which are typically less responsive to current checkpoint inhibitors.
• Global co-development and co-commercialization agreement with Bristol Myers Squibb (BMS) for BNT327, including a $1.5 billion upfront payment and $2 billion in non-contingent anniversary payments through 2028, plus up to $7.6 billion in additional milestones.
• BNT327 received Orphan Drug Designation from the FDA for the treatment of small cell lung cancer (SCLC).
• BNT211 (CAR-T) granted Priority Medicines (PRIME) designation by the EMA for testicular germ cell tumors and Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA.
• BNT323/DB-1303 (HER2 ADC) received Fast Track and Breakthrough Therapy designation from the FDA for advanced endometrial cancer.
• BNT324/DB-1311 (B7H3 ADC) received Fast Track designation from the FDA for metastatic castration-resistant prostate cancer (mCRPC) and Orphan Drug designation for esophageal squamous cell carcinoma.
• BNT325/DB-1305 (TROP2 ADC) received Fast Track designation from the FDA for platinum-resistant ovarian cancer (PROC).
• Expansion of strategic partnership with CEPI to establish RNA vaccine manufacturing in Kigali, Rwanda, supported by up to $145 million in funding.
• Received a grant of up to 129 million euros over ten years from the UK Government to broaden R&D activities in the UK.
• Maintained a strong balance sheet with approximately 16.0 billion euros in total cash, cash equivalents, and security investments as of June 30, 2025.
• Reported a 40.2% revenue growth for the six months ended June 30, 2025, compared to the same period in 2024.
• Operating loss decreased by 30% and net loss decreased by 29% for the six months ended June 30, 2025, compared to the same period in 2024.
• Successfully settled contractual disputes with the NIH (payment of $791.5 million, with $364.5 million reimbursed by Pfizer) and UPenn (up to $467.0 million, with up to $170.0 million reimbursed by Pfizer).
• Entered into settlement arrangements with GSK and CureVac to resolve pending patent litigation in the US, including a non-exclusive license for BioNTech and payments to GSK and CureVac, with Pfizer reimbursing a portion.
• Final judgment of noninfringement in the Alnylam patent litigation was entered in favor of BioNTech and Pfizer.
• The Ladewig securities class action complaint against BioNTech and its officers/directors was dismissed.

Negatives

• Expected continued decrease in demand for the COVID-19 vaccine, which currently accounts for a majority of total revenues.
• Uncertainty in COVID-19 vaccine demand and supply has led to, and may continue to result in, significant inventory write-downs and cancellations of contract manufacturing orders.
• Reliance on governmental authorities, private health insurers, and other third-party payors for coverage and adequate reimbursement levels for product candidates, with potential for delayed or denied payments.
• Challenges in increasing marketing and sales capabilities independently for product candidates outside of Germany and Trkiye.
• Operating results may fluctuate significantly, making future operating results difficult to predict, and potentially leading to stock price declines if expectations are not met.
• Incurred significant losses in the past and expects to incur a net loss for the 2025 financial year.
• Substantial additional financing may be required to achieve goals, with a risk of not obtaining capital on acceptable terms or at all, potentially delaying or terminating product development programs.
• CureVac shareholders will experience dilution in their ownership stake in BioNTech (estimated 4% to 6%) following the acquisition.
• CureVac shareholders who do not tender their shares in the offer may be subject to Dutch dividend withholding tax on the cancellation consideration in the post-offer reorganization.
• Risk of inability to successfully integrate CureVac's business and realize anticipated synergies within the anticipated timeframe.
• Potential for unknown liabilities and unforeseen increased expenses, delays, or regulatory conditions associated with the CureVac acquisition.
• Risk of not retaining key CureVac Group employees post-acquisition.
• Counterparties to certain significant agreements with the CureVac Group may exercise contractual rights (e.g., termination rights) due to the change in control.
• BioNTech expects to incur substantial expenses related to the CureVac acquisition and integration, potentially exceeding anticipated savings in the near term.
• The pendency of the CureVac acquisition could adversely affect the business and operations of both BioNTech and CureVac due to delayed decisions and employee uncertainty.
• Provisions in the Purchase Agreement could discourage potential competing acquirers of CureVac or result in lower competing offers.
• Shareholder litigation against BioNTech and CureVac related to the transaction could result in injunctions, damages, or adverse effects on the combined company's business.
• The share capital increase process under German law may result in an extended settlement period for Offer ADSs, with no interest for tendering CureVac shareholders.
• Significant volatility in the market price of BioNTech ADSs is expected to continue.
• Acquisitions, joint ventures, and collaborations may increase capital requirements, dilute shareholders, cause debt, or assume contingent liabilities, and benefits may not be realized.
• Ongoing patent litigation with Moderna, Arbutus/Genevant, GSK, and Promosome, with uncertain outcomes and potential for substantial costs, liabilities, or restrictions on commercialization.
• The malaria vaccine program (BNT165) is on clinical hold by the FDA.
• Pfizer opted out of further joint development of the shingles vaccine program (BNT167), and BioNTech also decided to opt-out, leading to program wind-down.
• The Phase 2 clinical trial for autogene cevumeran (iNeST) in adjuvant colorectal cancer crossed the futility boundary, indicating it did not meet its primary efficacy endpoint, though the trial will continue.
• Development programs for BNT315/GEN1055 and BNT322/GEN1056 were discontinued due to strategic evaluation.
• Dependence on single-source or a small number of suppliers for critical components and materials poses supply chain risks.
• Manufacturing processes for novel technologies are complex and may encounter difficulties in production, product release, shelf life, testing, storage, or shipping.
• Regulatory and operational risks associated with the physical and digital infrastructure at manufacturing facilities, including potential malfunctions or cybersecurity breaches.
• Stringent and evolving privacy laws (e.g., GDPR, US, China) and AI regulations could increase compliance costs, restrict data use, or lead to penalties.
• The German foreign investment screening regime may restrict certain non-EU/non-EFTA investments in BioNTech.
• As a foreign private issuer, BioNTech is exempt from certain U.S. securities laws and Nasdaq rules, which may limit information available to investors.
• Insurance policies are expensive and may not adequately protect against all business risks or liabilities.
• Adverse developments affecting financial institutions could adversely affect BioNTech's operations and liquidity.
• Risk of fraud or other misconduct by employees, principal investigators, and consultants.
• Potential for illegal distribution and sale of counterfeit versions of products, harming financial performance or reputation.
• Risk of product recalls due to manufacturing errors, design/labeling defects, or other issues.
• Issues in the development and use of AI, combined with an uncertain regulatory environment, may result in reputational harm or liability.
• Failure to effectively monitor and respond to environmental, social, and governance (ESG) matters may impose unexpected costs or reputational harm.

Risks

• Demand for our COVID-19 vaccine, though difficult to predict, is expected to continue to decrease in the near future. Changing market dynamics will impact our revenues, which currently depends heavily on sales of our COVID-19 vaccine, and result in challenges relating to production of our COVID-19 vaccine.
• The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities, private health insurers and other third-party payors provide coverage and adequate reimbursement levels and implement pricing policies favorable to our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, and/or delayed payments from government authorities could limit our ability to market those products and decrease our ability to generate revenues.
• If we are unable to continue to increase our marketing and sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates effectively in the United States and other jurisdictions, if approved, or generate sufficient product sales revenue.
• Our reported commercial revenues are based in part on preliminary estimates of COVID-19 vaccine sales and costs from Pfizer that are likely to change in future periods, which may impact our reported financial results.
• We may be unsuccessful in adapting our COVID-19 vaccine or developing future versions of our COVID-19 vaccine to protect against variants of the SARS-CoV-2 virus, and even if we are successful, a market for vaccines against these variants may not develop and our ability to continue to generate income from sales of our COVID-19 vaccine is uncertain.
• If we discover safety issues with our products, including our COVID-19 vaccine, that were not known at the time of approval, commercialization efforts for our products could be negatively affected, approved products could lose their approval or sales could be suspended, we could be subject to product liability claims and our business and reputation could be materially harmed.
• Government policies, including relating to manufacturing, export controls, or tariffs, and negative public perception regarding vaccines and mRNA-based therapeutics could severely and adversely impact the manufacturing and sales of our COVID-19 vaccine and other product candidates we may develop, if approved.
• We face significant competition with other makers of COVID-19 vaccines and may be unable to maintain a competitive market share for our COVID-19 vaccine.
• Our COVID-19 vaccine is sensitive to temperature, shipping and storage conditions and could be subject to risk of loss or damage.
• We are developing other product candidates and services in an environment of rapid technological and scientific change, and our failure to effectively compete would prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do and we may not be able to compete successfully.
• The market opportunities for some of our product candidates may be small due to the rarity of the disease, or limited to those patients who are ineligible for or have failed prior treatments. As the target patient populations for some of our programs are small, we may be unable to achieve or maintain profitability in future periods without obtaining regulatory approval for additional indications.
• Our ability to achieve or maintain profitability in future periods depends in part on our and our collaborators ability to penetrate global markets, where we would be subject to additional regulatory burdens and other risks and uncertainties associated with international operations that could materially adversely affect our business.
• Even if we obtain regulatory approval for our product candidates, the products may not gain the market acceptance among physicians, patients, hospitals, treatment centers and others in the medical community necessary for commercial success.
• Coverage and reimbursement may be limited or unavailable or change in the future in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.
• The advancement of healthcare reform legislation and changes to the regulatory environment in the United States, the European Union and elsewhere may increase the difficulty and cost for us to obtain marketing approval of and commercialize any product candidates we or our collaborators develop and may adversely affect the prices for such product candidates.
• Drug marketing and reimbursement regulations in the European Union and elsewhere may materially affect our ability to market and receive coverage for our products in the member states of the European Union and elsewhere.
• Our operating results may fluctuate significantly, which makes our future operating results difficult to predict. If our operating results fall below expectations, the price of the ADSs representing our ordinary shares could decline.
• We may encounter difficulties in developing and expanding our company and managing such development and expansion, which could disrupt our operations.
• Long-term sustainable profitability is difficult to achieve and maintain over time and is highly dependent on various factors.
• We have incurred significant losses in the past and we may incur significant losses in the future.
• The amount of, and our ability to use, net operating losses and research and development credits to offset future taxable income may be subject to certain limitations and uncertainty. In addition, pending and future tax audits within our Group, disputes with tax authorities and changes in tax law or fiscal regulations could lead to additional tax liabilities.
• Under German tax laws, we are obligated to withhold a percentage of wage tax and social security contributions on personnel expenses if contract services providers are considered to be our internal employees and remit those withholdings to German tax authorities and social security institutions. Late payments may subject us to penalties and fees.
• We may require substantial additional financing to achieve our goals, and a failure to obtain this capital on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.
• We have various international trade obligations, including customs value calculation, customs tariff number classification and other related securities requirements. Late payments to customs authorities may subject us to penalties and fees.
• As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws, as well as Nasdaq rules, and we are permitted to file less information with the SEC than U.S. companies. This may limit the information available to holders of the ADSs and may make our ordinary shares and the ADSs less attractive to investors.
• Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.
• Adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, such as actual events or concerns involving liquidity, defaults or non-performance, could adversely affect our operations and liquidity.
• Our business is dependent on the successful development, regulatory approval and commercialization of product candidates based on our technology platforms. If we and our collaborators are unable to obtain approval for and effectively commercialize our product candidates for the treatment of patients in their intended indications, our business would be significantly harmed.
• Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control. Clinical trials of our product candidates may be delayed, certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, and we may have difficulty recruiting patients to participate in clinical trials, any of which can affect our ability to fund our company and would have a material adverse impact on our business.
• We and our collaborators or other contractors or consultants depend on information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.
• mRNA drug development carries substantial clinical development and regulatory risks. We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA and regulatory authorities in other jurisdictions have limited experience with commercial development of several of our technologies.
• Our product candidates may not work as intended, may cause undesirable effects or may have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
• Clinical trials are strictly regulated and monitored by regulatory agencies, ethics committees, and sponsors. Despite this rigorous oversight, unexpected events may occur that could adversely impact patients safety and/or affect our ability to obtain regulatory approvals and, if approved, commercialize our product candidates.
• Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all and would have an adverse effect on our business.
• If we or our collaborators encounter difficulties enrolling participants in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
• We, our collaborators, and other third parties on whom we rely conduct various activities, including research, clinical trials, manufacturing and, where approved, marketing, in jurisdictions across the globe. Such activities are subject to a variety of risks which could materially and adversely affect our business.
• Interim top-line and preliminary data from studies or trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.
• Results of earlier studies and trials of our product candidates may not be predictive of future trial results.
• Our planned clinical trials or those of our collaborators may be less efficacious or may reveal significant adverse events not seen in our preclinical or nonclinical studies and may result in a safety profile that could delay or terminate clinical trials, or delay or prevent regulatory approval or market acceptance of any of our product candidates.
• If we are not successful in discovering, developing and commercializing additional product candidates beyond our current portfolio, our ability to expand our business and achieve our strategic objectives would be impaired.
• Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified senior management and scientific personnel.
• Our employees, principal investigators and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could have an adverse effect on the results of our operations.
• Employment-related disputes, including employee litigation and unfavorable publicity, could negatively affect our future business.
• The illegal distribution and sale by third parties of counterfeit versions of our COVID-19 vaccine, or, if approved, our other product candidates, could have a negative impact on our financial performance or reputation.
• Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of our current or future product candidates.
• If our products become subject to a product recall, it could harm our reputation, business and financial results.
• Issues in the development and use of AI, combined with an uncertain regulatory environment, may result in reputational harm, liability or other adverse consequences to our business.
• Our ability to effectively monitor and respond to the rapid and ongoing developments and expectations relating to environmental, social and governance matters, including related social expectations and concerns, may impose unexpected costs or result in reputational or other harm that could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the price of ADSs representing our ordinary shares to decline.
• Our COVID-19 vaccine and product candidates are based on novel technologies and they may be complex and difficult to manufacture. We may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping. If we or any of the third-party manufacturers we work with encounter such difficulties, our ability to supply materials for clinical trials or any approved product could be delayed or stopped.
• Our inability to manufacture sufficient or appropriate quantities of our COVID-19 vaccine or any of our product candidates, or our failure to comply with applicable regulatory requirements, could materially and adversely affect our business.
• We are dependent on a number of equipment providers who are also implementing novel technology. Further, we have developed our own custom manufacturing equipment for certain of our product candidates. If such equipment malfunctions or we encounter unexpected performance issues, we could encounter delays or interruptions to clinical and commercial supply.
• Certain of our product candidates are uniquely manufactured for each patient and we may encounter difficulties in production, particularly with respect to scaling our manufacturing capabilities. If we or any of the third-party manufacturers with whom we contract encounter these types of difficulties, our ability to provide such product candidates for clinical trials or, if approved, products for patients could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.
• We are subject to regulatory and operational risks associated with the physical and digital infrastructure at both our internal manufacturing facilities and at those of our external service providers.
• We are subject to significant regulatory oversight with respect to manufacturing our products and product candidates. Our manufacturing facilities or the manufacturing facilities of our third-party manufacturers or suppliers may not meet regulatory requirements. Failure to meet GMP requirements set forth in regulations promulgated by the FDA, the EMA and other comparable regulatory authorities could result in significant delays in and increased costs of our products.
• We rely on third parties in the conduct of significant aspects of our preclinical studies and clinical trials and intend to rely on third parties in the conduct of future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or fail to meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.
• We and our collaborators rely on third parties to manufacture certain of our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.
• Our existing collaborations, or any future collaboration arrangements that we may enter into, may not be successful, which could significantly limit the likelihood of receiving the potential economic benefits of the collaboration and adversely affect our ability to develop and commercialize our products and product candidates.
• If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our research, development and commercialization plans.
• We are dependent on single source or a small number of suppliers for some of the components and materials used in, and the processes required to develop, our COVID-19 vaccine and our product candidates.
• If our efforts to obtain, maintain, protect, defend and/or enforce the intellectual property related to our COVID-19 vaccine or our product candidates and technologies are not adequate, we may not be able to compete effectively in our market.
• Other companies or organizations may challenge our intellectual property rights or the intellectual property rights of our partners or may assert intellectual property rights that prevent us or our partners from developing and commercializing our COVID-19 vaccine or our product candidates and other technologies.
• We may not be successful in obtaining, maintaining, protecting or defending the necessary intellectual property rights to allow us to identify and develop product candidates, and test product components and manufacturing processes for our development pipeline.
• The lifespans of our patents may not be sufficient to effectively protect our products or product candidates, technologies and business.
• If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.
• If we fail to comply, or are viewed to have failed to comply, with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors or other third parties, we could lose license rights that are important to our business or suffer monetary losses.
• Some of our in-licensed intellectual property has been discovered through government-funded programs and thus may be subject to federal regulations such as march-in rights and certain reporting requirements, and compliance with such regulations may limit our exclusive rights and our ability to contract with manufacturers.
• Our current proprietary position for certain products and product candidates depends upon our owned or in-licensed patent filings covering components, manufacturing-related methods, formulations and/or methods of use, which may not adequately prevent a competitor or other third party from using the same product candidate for the same or a different use.
• Intellectual property rights of third parties could adversely affect our ability to commercialize our product(s) and product candidates, and we might be required to litigate or obtain licenses from third parties in order to develop, test or market our product(s) and product candidates.
• We may be involved in lawsuits or other legal proceedings to protect or enforce our intellectual property or the intellectual property of our licensors, or to defend against third-party claims that we infringe, misappropriate or otherwise violate such third partys intellectual property, each of which could be expensive, time consuming and unsuccessful.
• Changes in patent law in the United States or in other countries could diminish the value of patents in general, thereby impairing our ability to protect our products.
• If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
• We may be subject to claims that we have wrongfully hired an employee from a competitor, or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties, including alleged trade secrets of their former employers.
• We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
• We will not seek to protect our intellectual property rights in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.
• Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
• The FDA, the EMA or other comparable regulatory authorities may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.
• Our COVID-19 vaccine and any other product candidates for which we receive approval or emergency use authorization are subject to continuing regulatory oversight, and we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. We may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products or product candidates.
• We may not be able to develop or obtain approval for companion diagnostics required for commercialization of some of our product candidates.
• Because we are developing some of our product candidates for the treatment of diseases in which there is little clinical experience and, in some cases, using new endpoints or methodologies, the FDA, the EMA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.
• We may not be able to file INDs with the FDA, clinical trial applications with the competent authorities of the member states of the European Union or similar applications with other comparable regulatory authorities to commence additional clinical trials on the timelines we expect, and even if we are able to, one or more of these regulatory authorities may not permit us to proceed.
• We may seek Orphan Drug Designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with Orphan Drug Designation, including market exclusivity, which may cause our revenues, if any, to be reduced.
• We may seek Breakthrough Therapy or Fast Track designation for one or more of our product candidates, but we may not receive such designations. Even if we do, it may not lead to a faster development or regulatory review or approval process, and it may not increase the likelihood that such product candidates will receive marketing approval.
• We expect some of the product candidates we develop will be regulated as biologics in the United States and therefore they may be subject to competition from biosimilars approved through an abbreviated regulatory pathway.
• Some of our product candidates are classified as gene therapies by the FDA and the EMA, and the FDA has indicated that our product candidates will be reviewed within its Center for Biologics Evaluation and Research. Even though our mRNA product candidates are designed to have a different mechanism of action from gene therapies, the association of our product candidates with gene therapies could result in increased regulatory burdens, impair the reputation of our product candidates, or negatively impact our platform or our business.
• The regulatory landscape that will govern our product candidates is uncertain. Regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.
• We may be unable to obtain regulatory approval for our product candidates under applicable international regulatory requirements. The denial or delay of such approval would delay commercialization of our product candidates and adversely impact our potential to generate revenues, our business and our results of operations.
• A third-party investigational product candidate used in combination with our product candidates may be unable to obtain regulatory approval, which may delay commercialization of our product candidates.
• Governmental investigations and inquiries with respect to our COVID-19 vaccine and any other product candidates for which we receive approval or emergency use authorization may adversely affect our business, financial condition and results of operations.
• We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
• We are subject to certain anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.
• We are subject to stringent privacy laws, information security policies and contractual obligations governing the use, processing, and cross-border transfer of personal information and our data privacy and security practices.
• If we or our third-party suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.
• Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.
• The CureVac Group is exposed to risks relating to an advance purchase agreement with the European Commission, including risk of repayments and fines, which could affect BioNTech following closing of the Transactions.
• Following the Transactions contemplated by the Purchase Agreement, BioNTech may be unable to integrate the businesses of BioNTech and the CureVac Group successfully and realize the anticipated synergies and other benefits of the Transactions or do so within the anticipated timeframe.
• Following the Transactions, BioNTech may be unable to retain key CureVac Group employees.
• Counterparties to certain significant agreements with the CureVac Group may exercise contractual rights under such agreements in connection with the Transactions.
• BioNTech expects to incur substantial expenses related to the Transactions.
• The pendency of the Transactions could adversely affect the business and operations of BioNTech and the CureVac Group.
• The Purchase Agreement contains provisions that could discourage a potential competing acquirer of CureVac or could result in a competing proposal being at a lower price than it might otherwise be.
• Shareholder litigation against BioNTech and CureVac could result in an injunction preventing completion of the Transactions, the payment of damages in the event the Transactions are completed, and/or may adversely affect the combined companys business, financial condition, or results of operations following the Transactions.
• The Company must implement share capital increases to create the Offer Consideration, which will result in an extended settlement and may delay the closing of the Transactions. Tendering CureVac Shareholders will not receive any interest or other consideration as a result of this extended settlement.
• We have experienced and may continue to experience significant volatility in the market price of the BioNTech ADSs.
• Acquisitions, joint ventures and collaborations may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. We may not realize the benefits of these acquisitions, joint ventures or collaborations.
• The Company's articles of association designate specific courts in the United States as the exclusive forum for certain U.S. litigation that may be initiated by our shareholders, which could limit our shareholders ability to obtain a favorable judicial forum for disputes with us.
• Holders of the BioNTech ADSs may not be able to participate in any future preemptive subscription rights issues or elect to receive dividends in shares, which may cause additional dilution to their holdings.
• Our principal shareholders and management own a significant percentage of our ordinary shares and will be able to exert significant control over matters subject to shareholder approval.
• The large number of shares eligible for sale or subject to rights requiring us to register them for sale could cause the market price of the BioNTech ADSs to drop significantly, even if our business is performing well.
• The acquisition of a substantial interest in the Company by non-EU/non-EFTA investors requires government approval, which may restrict certain investments and limit demand for the BioNTech ADSs.
• Holders of the BioNTech ADSs are not treated as shareholders of the Company and will not have the same voting rights as the Company's shareholders, which may affect the value of the BioNTech ADSs.

Future Outlook

BioNTech expects to incur a net loss for the 2025 financial year. The company aims to launch its first oncology product as early as 2026 and establish itself as an innovative oncology company with several approved products in various indications by 2030. It plans to continue investing in R&D, expanding its global development organization, and diversifying its therapeutic area footprint across autoimmune diseases, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, and regenerative medicines. The company anticipates continued seasonal COVID-19 vaccination demand and is preparing for the global commercial roll-out of a new variant-adapted COVID-19 vaccine.

Management Comments

• We believe we are a global next-generation immunotherapy company aiming to pioneer novel medicines against cancer, infectious diseases and other serious diseases.
• Our fully integrated model combines decades of research in immunology with a multi-technology innovation engine, Good Manufacturing Practice manufacturing, translational drug discovery, clinical development, commercial capabilities, computational medicine, data science and artificial intelligence, and machine learning, capabilities to discover, develop and commercialize our marketed product and product candidates.
• We believe our multi-technology combination of platforms and product candidates positions us as pioneers in the field of individualized, patient-centric therapeutic approaches in oncology and infectious diseases.
• Our primary focus is oncology, where we endeavor to address the full continuum of cancer from early to late disease stages.
• Our key objectives are to develop an innovative immunotherapy pipeline in oncology targeting multiple product approvals in the coming years and to build a sustainable respiratory infectious disease vaccine business based on the BioNTech-Pfizer Comirnaty franchise.
• We believe individualized mRNA cancer immunotherapies have the potential to change the current standard of care and improve overall survival by delaying or preventing recurrence or cancer metastasis.
• We are committed to translating science into survival for patients by advancing BioNTechs strategy and executing it to become a global immunotherapy powerhouse with multiple approved products and revenue streams.
• We believe scaling up manufacturing for mRNA can best be executed as part of a proprietary manufacturing approach, rather than as part of an outsourcing strategy.
• We believe we are well positioned to continue executing our vision of pioneering novel medicines against cancer, infectious diseases and other serious diseases.

Industry Context

The pharmaceutical market is intensely competitive and rapidly changing, particularly in biotechnology, mRNA technologies, oncology, and infectious diseases. BioNTech positions itself as a 'global next-generation immunotherapy company' and 'pioneers in the field of individualized, patient-centric therapeutic approaches.' The acquisition of CureVac is framed as a strategic move to expand capabilities in mRNA-based oncology, complementing existing efforts in immunomodulators and ADCs. The global market for cancer immunotherapies is projected to grow significantly (15% CAGR to $31.3 billion by 2030), driven by increasing cancer prevalence, acceptance of immunotherapy, and R&D. The COVID-19 vaccine market is transitioning from a pandemic to an endemic stage, leading to decreased demand but a continued need for adapted seasonal vaccines. The company also notes the evolving regulatory landscape for AI in healthcare and the increasing scrutiny on ESG matters.

Comparison to Industry Standards

• BioNTech's COVID-19 vaccine, Comirnaty, was the first-ever approved mRNA-based product and, to its knowledge, the fastest developed prophylactic vaccine from viral sampling to approval.
• The company's multi-technology combination of platforms and product candidates positions it as pioneers in individualized, patient-centric therapeutic approaches in oncology and infectious diseases.
• BNT327 showed encouraging clinical activity in various tumor types, including PD-L1-low and -negative tumors, which have typically been less responsive to current checkpoint inhibitor treatments.
• CureVac's UPEC mRNA vaccine candidates demonstrated superior immunogenicity compared to recombinant protein-based vaccines in preclinical studies.
• The company's manufacturing turnaround time for individualized immunotherapies (iNeST) has decreased from over three months to under six weeks, with a target of less than 28 days, demonstrating significant progress toward industry-leading efficiency.
• BioNTech's Marburg facility is one of the largest mRNA vaccine manufacturing sites worldwide with an annual capacity of up to three billion doses, indicating a leading position in mRNA production scale.
• The UK Government grant of up to 129 million euros is noted as 'one of the largest grants of its kind in U.K. history for a pharmaceutical company.'
• BioNTech maintained its Prime status from ISS ESG and remained in the benchmark Top 10% of all rated companies in the pharmaceutical and biotechnology sector, indicating strong ESG performance relative to peers.
• The company improved its overall rating from Bto B in the Corporate Rating 2024 by ISS, and was included in the S&P Global Sustainability Yearbook 2025 for the first time, scoring within the top 15% of its industry.

Management Changes

Corporate Governance

Legal Proceedings

• NIH Settlement Agreement (December 20, 2024): BioNTech paid $791.5 million to NIH, resolving claimed royalties for 2020-2023. Amended NIH License Agreement. Pfizer to reimburse BioNTech $364.5 million.
• UPenn Settlement Agreement (March 27, 2025): BioNTech to pay up to $467.0 million to UPenn ($400.0 million for 2020-2023 royalties paid in June 2025, up to $15.0 million for vaccine alliance extension, $52.0 million for R&D investment fund). Amended collaboration & license agreements. Pfizer to reimburse BioNTech up to $170.0 million.
• GSK/CureVac Settlement Arrangements (August 7, 2025): Resolved pending patent litigation in US. BioNTech paid $370 million to GSK (of which $320 million cash) and $370 million to CureVac (contingent on offer closing). BioNTech to pay 1% royalty on US sales of Licensed Products to GSK and CureVac from Jan 1, 2025. Subject to offer closing, BioNTech to pay $130 million to GSK for worldwide license, with Pfizer reimbursing $80 million and half of future royalties.
• Alnylam Settlement Agreement (August 29, 2025): Resolved patent litigation with final judgment of noninfringement in favor of BioNTech and Pfizer. Alnylam agreed not to appeal.
• CureVac Proceedings (Germany): Infringement lawsuits (EP122, DE961, DE974, DE575, EP668, EP755, DE123, DE130) in Dsseldorf Regional Court. EP122 nullified by Federal Patent Court (appealed by CureVac, hearing July 2026). DE961 and DE974 cancelled by German Patent and Trademark Office (appealed by CureVac). DE575 and DE123 waived by CureVac. EP668 and EP755 upheld in amended form by EPO Opposition Division (appealed by BioNTech, hearings Sept 2026 and Nov 6, 2025 respectively).
• CureVac Proceedings (United States): Lawsuit in U.S. District Court for Eastern District of Virginia alleging infringement of multiple U.S. patents. Trial rescheduled for September 8, 2025.
• CureVac Proceedings (United Kingdom): UK High Court found EP668 and EP755 invalid (appealed by CureVac, denied by UK Appeals Court). EP122 UK designation revoked.
• Moderna Proceedings (Germany): Lawsuit in Dsseldorf Regional Court alleging infringement of EP949 and EP565. EP565 revoked by EPO (appealed by Moderna, hearing Jan 27, 2026). EP949 found valid in amended form by EPO (appealed by BioNTech, hearing Sept 2026). Dsseldorf Regional Court found infringement of EP949 (appealed by BioNTech and Pfizer).
• Moderna Proceedings (United Kingdom): UK High Court found EP565 invalid and EP949 valid and infringed. Moderna's Patent Pledge provided consent until March 2022. UK Appeals Court denied Moderna's appeal for EP565. UK Court of Appeal upheld EP949 validity (BioNTech applied to appeal to UK Supreme Court).
• Moderna Proceedings (United States): Lawsuit in U.S. District Court for District of Massachusetts alleging infringement of U.S. Patent Nos. 10,898,574; 10,702,600; 10,933,127. Stayed pending inter partes review. PTAB found all challenged claims of U.S. Patent Nos. 10,933,127 and 10,702,600 unpatentable (appealed by Moderna).
• Moderna Proceedings (Netherlands, Ireland, Belgium): Lawsuits alleging infringement of EP949 and EP565 are pending or stayed.
• Arbutus and Genevant Proceedings: Lawsuit in U.S. District Court for District of New Jersey alleging infringement of multiple U.S. patents. Pending. Genevant initiated arbitration against BioNTech for breach of license agreement.
• GlaxoSmithKline Proceedings: Lawsuits in U.S. District Court for District of Delaware, High Court of Ireland, and Unified Patent Court alleging infringement of multiple U.S. and European patents. Pending.
• Promosome Proceedings: Lawsuit in UPC Munich Division alleging infringement of EP 2 401 365. Pending.
• Ladewig Proceedings: Securities class action complaint dismissed by U.S. District Court for Southern District of New York. Plaintiffs have until Oct 30, 2025, to file a notice of appeal.

Related Party Transactions

• ATHOS KG, as the sole shareholder of AT Impf GmbH, has de facto control over BioNTech.
• Purchases of various goods and services from entities controlled by ATHOS KG amounted to 0.2 million euros in 2024, 0.3 million euros in 2023, and 0.3 million euros in 2022.
• Purchases of property and other assets from entities controlled by ATHOS KG amounted to 62.5 million euros in 2022.
• Key management personnel compensation for the Management Board was 13.0 million euros in 2024, 8.3 million euros in 2023, and 15.0 million euros in 2022.
• Key management personnel compensation for the Supervisory Board was 0.9 million euros in 2024, 0.6 million euros in 2023, and 0.5 million euros in 2022.
• Management Board members participated in share-based payment programs, including option exercises and RSU settlements, with significant cash outflows for related wage taxes and social security contributions.
• Helmut Jeggle, Chair of the Supervisory Board, holds functions and management positions at the company's indirect controlling shareholders and/or their affiliates, constituting a potential conflict of interest.

Stakeholder Impact

• Shareholders (BioNTech): Potential dilution from the CureVac acquisition (0.5% to 1.5% for existing shareholders). Volatility in ADS price due to market conditions, company performance, and litigation. Potential for increased value from strategic acquisitions and pipeline advancements.
• Shareholders (CureVac): Will receive BioNTech ADSs, becoming BioNTech shareholders. Dilution in ownership stake compared to current CureVac holdings (estimated 4% to 6%). Non-tendering shareholders may face Dutch dividend withholding tax.
• Employees (BioNTech): Workforce adjustments (creation of 800-1,200 FTEs, reduction of 950-1,350 FTEs) due to strategic optimization. Positive relationship with employees and works councils.
• Employees (CureVac): Uncertainty about future roles post-acquisition, potential for key employee departures. BioNTech plans to comply with existing employment terms and benefits.
• Customers: Continued supply of COVID-19 vaccines, development of new variant-adapted vaccines. Potential for new oncology and infectious disease treatments.
• Suppliers/Partners: Potential for disruption in relationships due to the acquisition. Dependence on single-source suppliers poses risks. Collaboration agreements (e.g., with Pfizer, BMS, DualityBio, OncoC4, Genmab) are crucial for R&D and commercialization.
• Regulatory Bodies: Ongoing scrutiny of drug development, manufacturing, and commercialization. Compliance with evolving regulations (e.g., AI, ESG, data privacy).
• Creditors: Financial position remains strong with substantial cash reserves, but ongoing losses and litigation could impact future financial health.

Next Steps

• BioNTech will commence the offer to acquire CureVac shares on October 21, 2025.
• The initial offer period will remain open until December 3, 2025.
• Determination of the final Exchange Ratio by November 25, 2025, and public announcement by November 26, 2025.
• Acceptance Time and publication of initial offer results by December 3, 2025.
• Commencement of a Subsequent Offering Period on December 4, 2025.
• Resolutions on the first share capital increase and related share issuance on or about December 4, 2025.
• Registration of the first Share Capital Increase on or about December 15, 2025.
• Onward delivery of Offer ADSs and cash for fractional ADSs to initial offer tendering shareholders on or about December 17, 2025.
• End of Subsequent Offering Period and publication of results on December 18, 2025.
• Resolutions on the second share capital increase and related share issuance on or about December 19, 2025.
• Registration of the second Share Capital Increase on or about January 2, 2026.
• Onward delivery of Offer ADSs and cash for fractional ADSs to subsequent offer tendering shareholders on or about January 6, 2026.
• CureVac expects to file an IND application for its UPEC vaccine candidate in the second half of 2025, aiming to initiate a Phase 1 study in the first half of 2026.
• A Part B data readout for CVGBM and a decision on advancing the program to Phase 2 are expected in the second half of 2025.
• Clinical trial application for CureVac's fully individualized cancer therapy (CVICaT) Phase 1 trial is planned for Q1 2026, with first-patient-in planned for H2 2026.
• BioNTech expects to continue building its pipeline towards a potential first oncology launch as early as 2026.
• Data from BNT327 Phase 2 clinical trial in locally advanced or metastatic TNBC and ES-SCLC are expected in 2025.
• Phase 3 clinical trial (ROSETTA Breast-01) evaluating pumitamig in combination with chemotherapy for TNBC is expected to start in 2025.
• Data from BNT323/DB-1303 cohort in advanced/recurrent endometrial cancer planned to be shared at a medical meeting in 2026.
• BioNTech plans to move into its new four-story building at An der Goldgrube 10 in Mainz in January 2026.
• Start of operations for the GMP manufacturing facility at Hechtsheimer Strae 2b in Mainz is planned for 2027.
• BioNTech commits to investing up to 1 billion euros over the next ten years in the UK for R&D activities.
• BioNTech plans to establish two new R&D centers and its UK headquarters in London.
• BioNTech intends to appeal the UK Court of Appeal's decision on EP949 to the UK Supreme Court.
• Moderna may appeal PTAB's decision finding U.S. Patent Nos. 10,933,127 and 10,702,600 unpatentable.
• Oral hearing for CureVac's appeal of EP122 nullification scheduled for July 2026.
• Oral hearing for BioNTech's appeal of EP949 validity decision scheduled for September 2026.
• Oral hearing regarding the validity of DE130 before the German Patent and Trademark Office scheduled for December 8, 2025.
• Hearing on EP668 and EP755 infringement scheduled for November 6, 2025.
• Hearing on EP949 appeal in Netherlands scheduled for September 22, 2025, with decision expected around December 9, 2025.
• Oral hearing for Promosome lawsuit in UPC Munich Division scheduled for May 2026.
• Plaintiffs in Ladewig v. BioNTech SE have until October 30, 2025, to file a notice of appeal.

Key Dates

Recommendation

While BioNTech is making significant strategic moves, including the acquisition of CureVac and a major collaboration with BMS, which promise long-term pipeline diversification and substantial upfront payments, the near-term financial outlook is negative with an expected net loss for 2025. The company faces numerous ongoing patent litigations with uncertain outcomes and has experienced clinical setbacks (malaria vaccine clinical hold, iNeST futility boundary crossed, program discontinuations). The declining COVID-19 vaccine revenue, while expected, adds to the near-term headwinds. The stock price has also shown significant volatility. Given the strong cash position and strategic long-term potential balanced against significant near-term operational and legal risks, a 'hold' recommendation is appropriate for a seasoned investor to monitor developments before making further investment decisions.

Keywords

BioNTech, CureVac, Acquisition, mRNA, Oncology, Infectious Disease, Vaccine, Biopharmaceutical, Clinical Trials, Regulatory Approval, Patent Litigation, Strategic Partnership, Biotech, Pharmaceutical, Mergers and Acquisitions, Risk Management, Capital Markets, Corporate Governance, ESG